<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The EGFR 3[prime] untranslated region (UTR) harbors a polyadenine repeat which is polymorphic (A13/A14) and undergoes somatic deletions in microsatellite instability (MSI) <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>These mutations could be oncogenic in colorectal tissue since they were shown to result into increased EGFR <z:chebi fb="2" ids="33699">mRNA</z:chebi> stability in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> cell lines </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: First, we determined in a case control study including 429 CRC patients corresponding to different groups selected or not on age of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:hpo ids='HP_0003674'>onset</z:hpo> and/or familial history and/or MSI, whether or not, the germline EGFR A13/A14 polymorphism constitutes a genetic risk factor for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>; second, we investigated the frequency of <z:hpo ids='HP_0001428'>somatic mutations</z:hpo> of this repeat in 179 CRC and their impact on EGFR expression </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: No statistically significant difference in allelic frequencies of the EGFR polyA repeat polymorphism was observed between <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients and controls </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0001428'>Somatic mutations</z:hpo> affecting the EGFR 3[prime]UTR polyA tract were detected in 47/80 (58.8%) MSI <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> versus 0/99 microsatellite stable (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MSS</z:e>) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Comparative analysis in 21 CRC samples of EGFR expression, between <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> and non malignant tissues, using two independent methods showed that <z:hpo ids='HP_0001428'>somatic mutations</z:hpo> of the EGFR polyA repeat did not result into an EGFR <z:chebi fb="2" ids="33699">mRNA</z:chebi> increase </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: Germline and somatic genetic variations occurring within the EGFR 3[prime]UTR polyA tract have no impact on <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> genetic risk and EGFR expression, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>Genotyping of the EGFR polyA tract has no clinical utility to identify patients with a high risk for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> or patients who could benefit from anti-EGFR antibodies </plain></SENT>
</text></document>